Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
about
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyUtilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other DiseasesEffects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouseRisks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisEfficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.Plasmapheresis for neurological disorders.Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107aFumarates for treatment of psoriasis.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
P2860
Q27011473-10E66BF6-290C-4718-91CE-6150BA563A53Q28078742-E9552E8D-004B-4CDA-89EA-9F8EBD4ED049Q28750219-FEC80F17-5E7B-4217-A077-28B30D7F5BD1Q33802186-41DCFD43-67D8-4F41-A4C8-133255246E6EQ33812932-88F64330-99EB-4FBF-930A-337CB162DB9EQ34627230-F7B87883-6870-4A69-B4D8-5DC7D9ED35ACQ36975701-9E015A45-EC65-48EB-8019-5D7763C16DF3Q37459099-A4E7B557-3A79-469C-8FEB-FB93B7E21FFEQ37600865-85B91126-0841-45A8-B89D-6809FB5176BBQ42138439-A6662F64-9EF7-4C97-84B7-D6511702C39FQ48268517-BC5EE82A-C5AE-40EA-880E-5A5CD468FE79Q49884884-0BD7436A-D495-4FBD-A697-FD9C9C20F3C0Q52806769-F576E7BE-567F-4751-BA2F-65687CA9214A
P2860
Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Fumarates for the treatment of ...... f action and clinical studies.
@en
Fumarates for the treatment of ...... f action and clinical studies.
@nl
type
label
Fumarates for the treatment of ...... f action and clinical studies.
@en
Fumarates for the treatment of ...... f action and clinical studies.
@nl
prefLabel
Fumarates for the treatment of ...... f action and clinical studies.
@en
Fumarates for the treatment of ...... f action and clinical studies.
@nl
P2093
P2860
P1476
Fumarates for the treatment of ...... f action and clinical studies.
@en
P2093
De-Hyung Lee
Martin Stangel
Ralf A Linker
P2860
P304
P356
10.1586/14737175.8.11.1683
P577
2008-11-01T00:00:00Z